China Interventional Cardiology
China's interventional cardiology market is heating up, especially with pVAD devices. What's new? A (Interventional Cardiologist - China): The biggest news is the approval of the first domestic percutaneous ventricular assist device (pVAD) in late 2025. For high-risk PCI in patients with severe coronary artery disease and low ejection fraction, pVAD provides superior hemodynamic support compared to IABP. It's a game-changer .
B (Medical Device Executive - China): 2026 is being called the "collective approval year" for pVAD. Over six domestic companies are in late-stage trials. This will break the monopoly of Abiomed's Impella, which was previously available only via special clinical need channels. Competition will drive down prices from the current ~$30,000 per device.
C (Hospital Procurement): The cost is still prohibitive for many provincial hospitals. Reimbursement codes are not fully established. We expect the national reimbursement list (NHSA) to include pVAD for high-risk PCI within 2-3 years, but until then, it's only available in top-tier academic centers.
D (Patient - Post-PCI): I had a high-risk stent placement. My doctor mentioned a "heart pump" but the cost was astronomical. I hope domestic devices make this life-saving technology accessible to ordinary Chinese patients, not just the wealthy.